Leucid Bio Unveils ‘Parallel CAR-T’ Platform Targeting Solid Tumors
Based On Veteran Researcher’s Innovation
The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.
You may also be interested in...
Single Patient Safety Concern Hits Allogene’s Off-The-Shelf CAR-T
Allogene is the frontrunner in the allogeneic CAR-T field but must assess whether or not its therapy could have caused a patient’s unexpected chromosomal abnormality.
Immunocore Could Gain Green Light For First T-Cell Receptor Drug In Early 2022
The UK biotech is the first company to file a T-cell receptor therapy with regulators, a class with potential to hit targets unreachable for antibodies and CAR-Ts.
Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage
Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.